|
× |
 |
Metabolic Risk Factors in Drug-Naive Patients With First-Episode Psychosis PDF |
$40.00 |
|
$40.00 |
|
× |
|
Association of Suicide and Antidepressant Prescription Rates in Japan, 1999-2003 PDF |
$40.00 |
|
$40.00 |
|
× |
|
Use of Treatment Services and Pharmacotherapy for Bipolar Disorder in a General Population-Based Mental Health Survey. PDF |
$40.00 |
|
$40.00 |
|
× |
|
A Preliminary Study of Luteal Phase Versus Symptom-Onset Dosing With Escitalopram for Premenstrual Dysphoric Disorder PDF |
$40.00 |
|
$40.00 |
|
× |
|
The Relationship Between Self-Reported Pain and Borderline Personality Symptomatology Among Internal Medicine Outpatients PDF |
$40.00 |
|
$40.00 |
|
× |
|
The Psychopharmacology of Violence With Emphasis on Schizophrenia, Part 1: Acute Treatment PDF |
$40.00 |
|
$40.00 |
|
× |
|
Medication Nonadherence and Treatment Outcome in Patients With Schizophrenia or Schizoaffective Disorder With Suboptimal Prior Response PDF |
$40.00 |
|
$40.00 |
|
× |
|
Relationships Between Obsessive-Compulsive Symptomatology and Severity of Psychosis in Schizophrenia: A Systematic Review and Meta-Analysis PDF |
$40.00 |
|
$40.00 |
|
× |
|
The Second Wave of the COVID-19 Tsunami and Mental Health: An Indian Perspective PDF |
$40.00 |
|
$40.00 |
|
× |
|
Low-Dose Clozapine in Acute and Continuation Treatment of Severe Borderline Personality Disorder PDF |
$40.00 |
|
$40.00 |
|
× |
|
Medication Status and Polycystic Ovary Syndrome in Women With Bipolar Disorder: A Preliminary Report PDF |
$40.00 |
|
$40.00 |
|
× |
|
Six-Month Outcomes From a Randomized Trial Augmenting Serotonin Reuptake Inhibitors With Exposure and Response Prevention or Risperidone in Adults With Obsessive-Compulsive Disorder PDF |
$40.00 |
|
$40.00 |
|
× |
|
Medication Supervision and Adherence of Persons With Psychotic Disorders in Residential Treatment Settings: A Pilot Study PDF |
$40.00 |
|
$40.00 |
|
× |
|
Quantitative and Qualitative Analysis of the Quality of Life of Individuals With Eating Disorders PDF |
$40.00 |
|
$40.00 |
|
× |
|
Withdrawal-Emergent Dyskinesia Following Abrupt Discontinuation of Desvenlafaxine PDF |
$40.00 |
|
$40.00 |
|
|
